ELISA detection of SARS-CoV-2 antibodies in saliva
Melanie MacMullan, Albina Ibrayeva, Kylie Trettner, Laura Deming, Sudipta Das, Frances Tran, Jose Ricardo Moreno, Joseph Casian, Prithivi Chellamuthu, Jeffrey Kraft, Kenneth Kozak, Fred Turner, Vladimir Slepnev, Lydia Le Page
Received date: 22nd August 2020
To facilitate containment of the COVID-19 pandemic currently active in the United States and across the world, options for easy, non-invasive antibody testing are required. Here we have adapted a commercially available, serum-based ELISA for use with saliva samples, achieving 84.2% sensitivity and 100% specificity in a set of 149 clinical samples. This strategy will enable widespread, affordable testing for patients who experienced this disease, whilst minimizing exposure risk for healthcare workers.
This is an abstract of a preprint hosted on a preprint server, which is currently undergoing peer review at Scientific Reports. The findings have yet to be thoroughly evaluated, nor has a decision on ultimate publication been made. Therefore, the results reported should not be considered conclusive, and these findings should not be used to inform clinical practice, or public health policy, or be promoted as verified information.